Skip to content
10-Q

Quarterly Report

ALDEYRA THERAPEUTICS, INC. ALDX

0000950170-25-071602

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 59.9M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $15.1M
Long Term Debt Q1 2025 · Dec 31, 2024 $15M
Short Term Debt Q1 2025 · Mar 31, 2025 $0
Short Term Debt Q1 2025 · Dec 31, 2024 $31.37K
Cash And Equivalents Q1 2025 · Mar 31, 2025 $50.35M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $54.53M
Current Liabilities Q1 2025 · Mar 31, 2025 $14.29M
Current Liabilities Q1 2025 · Dec 31, 2024 $18.6M
Total Liabilities Q1 2025 · Mar 31, 2025 $29.6M
Total Liabilities Q1 2025 · Dec 31, 2024 $33.6M
Current Assets Q1 2025 · Mar 31, 2025 $92.73M
Current Assets Q1 2025 · Dec 31, 2024 $104.07M
Total Assets Q1 2025 · Mar 31, 2025 $93.2M
Total Assets Q1 2025 · Dec 31, 2024 $104.61M
Shares Diluted Q1 2025 · Mar 31, 2024 59.41M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$9.97M
Stockholders Equity Q1 2025 · Mar 31, 2024 $113.42M
Stockholders Equity Q1 2025 · Dec 31, 2023 $119.8M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.14
Eps Basic Q1 2025 · Mar 31, 2024 −$0.14
Sga Expense Q1 2025 · Mar 31, 2024 $3.21M
Rd Expense Q1 2025 · Mar 31, 2024 $6.18M
Net Income Q1 2025 · Mar 31, 2024 −$8.08M
Operating Income Q1 2025 · Mar 31, 2024 −$9.39M